A Medical Cannabis Stock for Millennial Investors

The cannabis sector is still very young with enormous risks. There are great ideas in the space, especially when it comes to medical uses. Medipharm Labs Corp. (TSX:LABS) has an excellent business model that should grow over time. It is perfect for millennial investors with long time horizons.

| More on:
Top view of mixed race business team sitting at the table at loft office and working. Woman manager brings the document

Image source: Getty Images

I haven’t held the cannabis industry in high regard since the nascent industry began. It was a wild west type of investing, where stocks shot up and crashed on sentiment and feelings rather than on fundamentals. The only area of the cannabis space that held any weight in my mind was that of medical marijuana production.

Medical marijuana, after all, appears to have many positive attributes. It holds promise as a medicine in the treatment of epilepsy as well as many other ailments. In that regard, I stumbled upon one name that might be a decent pure-play in the medical marijuana sector.

However, this is an early-stage growth stock that I would only recommend for investors with long time horizons.

The oily names

Oil has primarily meant black gold for me over the years, but it turns out there is another type of oil worth looking into. Medipharm Labs Corp. (TSX:LABS) focuses on extracting medical-grade cannabis oil from marijuana plants. Its business is solely focused on extraction, a process that seems to have a wider moat than merely selling the commodity plant products.

Financial strength

The company had enormous growth in revenue over fiscal 2019. Revenue grew by 1,168% over that period. EBITDA also grew incredibly, increasing 2,844% in the same time frame. Gross profit increased by 973% and net income increased by 180%. Net income was positive for the year, which is quite amazing for a new company at this early stage of growth.

Of course, investors need to keep in mind that the company is a new one, which means that growth will be rapid in the early stages. After all, earnings and revenue started from a very low level making any increase seem huge on a percentage basis.

The company is new, though, and its share count is expanding. This will be dilutive to existing shareholders if Medipharm continues to issue shares. It also does not yet generate free cash flow due to its continued business investment and growth. 

Business model

There are two aspects of this business I find very appealing. The first is the focus on medical purposes. The attention to producing medical-grade oils puts this firmly into the high-demand medical marijuana business. It sells both its own brands of oil as well as unbranded types.

The Foolish takeaway

I am not a big fan of investing in cannabis stocks in general. It seems like recreational marijuana is a difficult business and the product itself is more of a commodity than anything. The oil extraction business is more technical, especially if you are aiming for medical-grade oil. Medipharm seems to have a greater moat around its business than the producers.

This is a new business that is very speculative in nature. However, if you are looking to invest in the burgeoning medical marijuana space, Medipharm is as good a bet as any. It does look set on building a business that fits a core need, has a product that is certainly growing in demand and is starting to grow in profitability.

If you are a millennial investor with a long time horizon who believes in the medical side of the cannabis industry, you might want to give Medipharm a try.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kris Knutson owns shares of MediPharm Labs.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »